Romaciclib (RVU120), a selective CDK8/19 inhibitor discovered at Ryvu Therapeutics in Kraków, is in development for AML, myelofibrosis, and low-risk MDS. Preclinical evidence and early clinical trials have demonstrated a favorable safety profile and signs of restored sensitivity to therapy (e.g., venetoclax in AML). With ongoing Phase II studies and a rapidly expanding clinical footprint, romaciclib is advancing from Ryvu’s discovery lab toward a potential new treatment option for patients worldwide.